Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base…
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…